Spherical Crystallization for Lean Solid-Dose Manufacturing (Part 1) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Spherical Crystallization for Lean Solid-Dose Manufacturing (Part 1)
In Part I of this article, the authors describe the materials and methods used in developing a screening strategy to accelerate the preparation and characterization of spherical agglomerates by spherical crystallization.


Pharmaceutical Technology
Volume 34, Issue 3, pp. 72-75

References

1. P. McKenzie et al., AIChE J. 52 (12), 3990–3994 (2006).

2. N.A. Lewis, Pharm. Technol. 30 (10), 94–108 (2006).

3. T. Lee and F.B. Hsu, Drug Dev. Ind. Pharm. 33 (11), 1273–1284 (2007).

4. T. Lee et al., Drug Dev. Ind. Pharm. 34 (5), 522–535 (2008).

5. Y. Kawashima and C.E. Capes, Powder Technol. 10 (1), 85–92 (1974).

6. Y. Kawashima and C.E. Capes, Powder Technol. 13 (2), 279–288 (1976).

7. Y. Kawashima, M. Okumura, and H. Takenaka, Science 216 (4550), 1127–1128 (1982).

8. Y. Kawashima et al., J. Pharm. Sci. 73 (10) 1407–1409 (1984).

9. Y. Kawashima, M. Okumura, and H. Takenaka, Powder Technol. 39 (1), 41–47 (1984).

10. Y. Kawashima et al., J. Pharm. Sci. 74 (11), 1152–1156 (1985).

11. A. Sano, Chem Pharm. Bull. 37 (8), 2183–2187 (1989).

12. Y. Kawashima et al., J. Pharm. Sci. 80 (5), 472–478 (1991).

13. K. Morishima et al., Powder Technol. 76 (1), 57–64 (1993).

14. Y. Kawashima et al., Powder Technol. 78 (2), 151–157 (1994).

15. K. Morishima et al., Int. J. Pharm. 105 (11), 11–18 (1994).

16. A.M. Garcia and E.S. Ghaly, J. Controlled Release 40 (3), 179–186 (1996).

17. A.H.L. Chow and M.W.M. Leung, Drug Dev. Ind. Pharm. 22 (4), 357–371 (1996).

18. U. Teipel, T. Heintz, and H.H. Krause, Propellants, Explosives, Pyrotechnics 25 (2), 81–85 (2000).

19. P. Szabó-Révész et al., Powder Technol. 114 (1), 118–124 (2001).

20. A.R. Paradkar et al., Drug Dev. Ind. Pharm. 28 (10), 1213–1220 (2002).

21. P. Szabó-Révész et al., J. Crystal Growth 237–239 (Part 3), 2240–2245 (2002).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here